Structural Modeling and Molecular Dynamics of the Immune Checkpoint Molecule HLA-G

被引:9
作者
Arns, Thais [1 ]
Antunes, Dinler A. [2 ]
Abella, Jayvee R. [2 ]
Rigo, Mauricio M. [2 ]
Kavraki, Lydia E. [2 ]
Giuliatti, Silvana [3 ]
Donadi, Eduardo A. [1 ]
机构
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Basic & Appl Immunol, Ribeirao Preto, Brazil
[2] Rice Univ, Dept Comp Sci, Houston, TX USA
[3] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Genet, Ribeirao Preto, Brazil
来源
FRONTIERS IN IMMUNOLOGY | 2020年 / 11卷
关键词
HLA-G; HLA-G1 soluble dimer; HLA-G5; isoform; molecular dynamics; structural bioinformatics; CLASS-I; G EXPRESSION; INHIBITORY RECEPTOR; PROTEIN-STRUCTURE; CRYSTAL-STRUCTURE; TUMOR-CELLS; WEB SERVER; ANTIGEN; COMPLEX; BINDING;
D O I
10.3389/fimmu.2020.575076
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HLA-G is considered to be an immune checkpoint molecule, a function that is closely linked to the structure and dynamics of the different HLA-G isoforms. Unfortunately, little is known about the structure and dynamics of these isoforms. For instance, there are only seven crystal structures of HLA-G molecules, being all related to a single isoform, and in some cases lacking important residues associated to the interaction with leukocyte receptors. In addition, they lack information on the dynamics of both membrane-bound HLA-G forms, and soluble forms. We took advantage of in silico strategies to disclose the dynamic behavior of selected HLA-G forms, including the membrane-bound HLA-G1 molecule, soluble HLA-G1 dimer, and HLA-G5 isoform. Both the membrane-bound HLA-G1 molecule and the soluble HLA-G1 dimer were quite stable. Residues involved in the interaction with ILT2 and ILT4 receptors (alpha 3 domain) were very close to the lipid bilayer in the complete HLA-G1 molecule, which might limit accessibility. On the other hand, these residues can be completely exposed in the soluble HLA-G1 dimer, due to the free rotation of the disulfide bridge (Cys42/Cys42). In fact, we speculate that this free rotation of each protomer (i.e., the chains composing the dimer) could enable alternative binding modes for ILT2/ILT4 receptors, which in turn could be associated with greater affinity of the soluble HLA-G1 dimer. Structural analysis of the HLA-G5 isoform demonstrated higher stability for the complex containing the peptide and coupled beta 2-microglobulin, while structures lacking such domains were significantly unstable. This study reports for the first time structural conformations for the HLA-G5 isoform and the dynamic behavior of HLA-G1 molecules under simulated biological conditions. All modeled structures were made available through GitHub (https://github.com/KavrakiLab/), enabling their use as templates for modeling other alleles and isoforms, as well as for other computational analyses to investigate key molecular interactions.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] The Potential of HLA-G-Bearing Extracellular Vesicles as a Future Element in HLA-G Immune Biology
    Rebmann, Vera
    Konig, Lisa
    Nardi, Fabiola da Silva
    Wagner, Bettina
    Santos Manvailer, Luis Felipe
    Horn, Peter A.
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [42] HLA-G impairs host immune response and predicts poor prognosis in pancreatic cancer
    Zhou, Li
    Niu, Zhe-Yu
    Liang, Zhi-Yong
    Zhou, Wei-Xun
    You, Lei
    Wang, Meng-Yi
    Yao, Lu-Tian
    Liao, Quan
    Zhao, Yu-Pei
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2015, 7 (10): : 2036 - 2044
  • [43] Expression analysis of immune-regulatory molecules HLA-G, HLA-E and IDO in endometrial cancer
    Ben Yahia, Hamza
    Boujelbene, Nadia
    Babay, Wafa
    Ben Safta, Ines
    Dhouioui, Sabrine
    Zemni, Ines
    Ayadi, Mohamed Ali
    Charfi, Lamia
    Ouzari, Hadda Imene
    Rebmann, Vera
    Rizzo, Roberta
    Mrad, Karima
    Driss, Maha
    Zidi, Ines
    HUMAN IMMUNOLOGY, 2020, 81 (06) : 305 - 313
  • [44] Immunosuppressive HLA-G molecule is upregulated in alveolar epithelial cells after influenza A virus infection
    LeBouder, Fanny
    Khoufache, Khaled
    Menier, Catherine
    Mandouri, Yassmina
    Keffous, Mahmoud
    Lejal, Nathalie
    Krawice-Radanne, Irene
    Carosella, Edgardo D.
    Rouas-Freiss, Nathalie
    Riteau, Beatrice
    HUMAN IMMUNOLOGY, 2009, 70 (12) : 1016 - 1019
  • [45] Structural studies on HLA-G: Implications for ligand and receptor binding
    Clements, Craig S.
    Kjer-Nielsen, Lars
    McCluskey, James
    Rossjohn, Jamie
    HUMAN IMMUNOLOGY, 2007, 68 (04) : 220 - 226
  • [46] Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia
    Wedenoja, Satu
    Yoshihara, Masahito
    Teder, Hindrek
    Sariola, Hannu
    Gissler, Mika
    Katayama, Shintaro
    Wedenoja, Juho
    Hakkinen, Inka M.
    Ezer, Sini
    Linder, Nina
    Lundin, Johan
    Skoog, Tiina
    Sahlin, Ellika
    Iwarsson, Erik
    Pettersson, Karin
    Kajantie, Eero
    Mokkonen, Mikael
    Heinonen, Seppo
    Laivuori, Hannele
    Krjutskov, Kaarel
    Kere, Juha
    EBIOMEDICINE, 2020, 59
  • [47] Immune modulation of HLA-G dimer in maternal-fetal interface
    Kuroki, Kirniko
    Maenaka, Katsurni
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (07) : 1727 - 1729
  • [48] Effect of HLA-G5 Immune Checkpoint Molecule on the Expression of ILT-2, CD27, and CD38 in Splenic B cells
    Rohn, Hana
    Lang, Cordula
    Schramm, Sabine
    Heinemann, Falko M.
    Trilling, Mirko
    Gaeckler, Anja
    Witzke, Oliver
    Horn, Peter A.
    Rebmann, Vera
    JOURNAL OF IMMUNOLOGY RESEARCH, 2022, 2022
  • [49] HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma
    Komohara, Yoshihiro
    Harada, Mamoru
    Ishihara, Yuki
    Suekane, Shigetaka
    Noguchi, Masanori
    Yamada, Akira
    Matsuoka, Kei
    Itoh, Kyogo
    ONCOLOGY REPORTS, 2007, 18 (06) : 1463 - 1468
  • [50] Expression and Functional Role of HLA-G in Immune Cells from Patients with Systemic Lupus Erythematosus
    Elizabeth Monsivais-Urenda, Adriana
    Baranda, Lourdes
    Alvarez-Quiroga, Crisol
    Abud-Mendoza, Carlos
    Gonzalez-Amaro, Roberto
    JOURNAL OF CLINICAL IMMUNOLOGY, 2011, 31 (03) : 369 - 378